SYNH Stock Recent News

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences. Chief Executive Officer Michelle Keefe and Chief Financial Officer Jason Meggs are scheduled to present at the following conferences:

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Syneos Health Inc's (NASDAQ: SYNH) Q1 revenue increased 10.5% on a reported basis and 11.7% on a constant currency (CC) basis to $1.34 billion, beating the consensus of $1.32 billion. Clinical Solutions revenue increased 8.4% (+9.6% CC) to $1.02 billion.

Syneos Health, Inc. (NASDAQ:SYNH ) Q1 2022 Earnings Conference Call April 29, 2022 8:00 AM ET Company Participants Ronnie Speight - SVP, IR Alistair Macdonald - CEO Michelle Keefe - CEO Jason Meggs - CFO Michael Brooks - Chief Operating Officer Conference Call Participants Eric Coldwell - Baird Casey Woodring - JP Morgan Christine Rains - William Blair Justin Bowers - Deutsche Bank David Windley - Jefferies Sandy Draper - Guggenheim Securities Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?